VanDeMark Chemical appoints Vice President of Global Sales & Business Development

James Romano will spearhead market integration of VanDeMark and newly acquired Framochem

VanDeMark Chemical has appointed James Romano as Vice President of Global Sales & Business Development. He will have supervisory responsibility for the sales staff of both VanDeMark and newly acquired Framochem, based in Kazincbarcika, Hungary.

VanDeMark is a leading North American manufacturer of phosgene and phosgene derivatives which are used in the pharmaceutical and other industries. Framochem, a wholly-owned subsidiary of VanDeMark, is a manufacturer of phosgene products based in Hungary.

Romano joins VanDeMark from Chemtura, where he was a Global Key Account Manager and Business Development Director. He has also served in sales management positions at Eastman Chemical and DSM Resins.

You may also like

Manufacturing

ARTES and Basic Pharma near completion of their joint rHSA project

The collaborative project involved the production of recombinant human serum albumin (rHSA)
Ingredients

Therapeutic: plozasiran for severe hypertriglyceridaemia

Patients with severe hypertriglyceridaemia (SHTG) have triglyceride levels greater than 500 mg/dL
Ingredients

Therapeutic: revumenib for leukaemia

Rearrangements in the mixed lineage leukaemia (MLL) gene — also known as KMT2A — lead to KMT2Ar acute leukaemia
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Subscribe now